Consequently, a variety of FGFR inhibitors (FGFRi) have been developed and achieved approval by the FDA as second line therapy in patients with unresectable locally advanced or metastatic iCCA with FGFR2 aberrations (7, 8). This evidence concerns the gene FGFR2 and infantile convulsions and choreoathetosis.